Preetam Shah
CIK 1787403 · See Remarks · last filed 2026-02-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$365.1K
Companies
3
Total Filings
14
Lifetime Open-Market Net
$41.8K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ELTX | See Remarks | 24,000 | $14.85 | $356.4K | $0 | 2 | 2026-02-03 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Chief Financial Officer | 335,960 | $221.38 | $74.37M | -$4.1K | 9 | 2024-10-02 |
| BCLI | EVP, CFO and Treasurer | 11,600 | $0.75 | $8.7K | $45.9K | 3 | 2020-12-31 |
Recent Filings · Page 2 of 2
14 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-09-03 | Cidara Therapeutics, Inc. (CDTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-12-31 | BCLI | Tax (F) | −25,000 | -$116.0K | EDGAR |
| 2019-12-27 | BCLI | Buy (P) | +11,600 | $45.9K | EDGAR |
| 2019-09-09 | BCLI | Grant (A) | +25,000 | $0 | EDGAR |
Showing 11–14 of 14
Prev
Page 2 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.